8-K: FDA Reissues Warning on PEDMARK Non-Substitutability, Citing Patient Safety Risks

The FDA has publicly reminded healthcare providers that PEDMARK, a drug used to reduce hearing loss in pediatric cancer patients, should not be substituted with other sodium thiosulfate products due to potential health risks.

Summary

• The U.S. Food and Drug Administration (FDA) has issued a public reminder that PEDMARK (sodium thiosulfate injection) is not substitutable with other sodium thiosulfate products.
• PEDMARK is the only FDA-approved therapy to reduce the risk of ototoxicity (hearing loss) associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors.
• The FDA is aware that some providers may be using other sodium thiosulfate products, including diluted versions, in place of PEDMARK.
• The FDA warns that such substitutions pose potential health risks, including exposure to potassium chloride, boric acid, and sodium nitrite, which are not present or are at different concentrations in PEDMARK.
• These risks include acute cardiac events, renal injury, and methemoglobinemia.

Sentiment

Score: 7

Explanation: The document is neutral to slightly positive as it highlights the FDA's proactive approach to patient safety, but also indicates a potential issue with the understanding or adherence to the prescribing label for PEDMARK.

Positives

• The FDA is actively ensuring the correct use of PEDMARK to protect patient safety.
• PEDMARK is the only FDA-approved therapy for its specific use, highlighting its unique formulation and safety profile.
• The FDA's public reminder reinforces the importance of adhering to the prescribing label for PEDMARK.

Negatives

• Some healthcare providers are using other sodium thiosulfate products as substitutes for PEDMARK, which is not recommended.
• These substitutions can lead to potential health risks due to differences in formulation and ingredients.
• The FDA's reminder indicates a potential issue with the understanding or adherence to the prescribing label for PEDMARK.

Risks

• The use of non-PEDMARK sodium thiosulfate products could lead to adverse health events in pediatric patients.
• There is a risk of increased exposure to potassium chloride, boric acid, and sodium nitrite when using substitute products.
• The potential for acute cardiac events, renal injury, and methemoglobinemia are significant concerns associated with these substitutions.

Future Outlook

The company will continue to focus on the commercialization of PEDMARK and Pedmarqsi.

Management Comments

• Fennec Pharmaceuticals Inc. announced that the FDA has issued a public reminder regarding the non-substitutability of PEDMARK.

Industry Context

This announcement highlights the importance of drug safety and adherence to prescribing labels in the pharmaceutical industry, particularly for specialized treatments like PEDMARK. It also underscores the FDA's role in monitoring and ensuring the correct use of approved medications.

Comparison to Industry Standards

• The FDA's action is consistent with its role in ensuring drug safety and efficacy, similar to actions taken with other specialized medications.
• The warning about non-substitutability is not unique to PEDMARK, as the FDA often issues such reminders for drugs with specific formulations or safety concerns.
• Other pharmaceutical companies also face similar challenges in ensuring proper use of their products, especially in cases where alternative products exist.

Stakeholder Impact

• Healthcare providers are reminded to adhere to the prescribing label for PEDMARK to ensure patient safety.
• Patients receiving cisplatin treatment are protected by the FDA's reminder, ensuring they receive the correct medication.
• Fennec Pharmaceuticals is impacted by the need to reinforce the correct use of their product.

Next Steps

• Fennec Pharmaceuticals will likely continue to monitor the situation and work with healthcare providers to ensure proper use of PEDMARK.
• The company may also engage in further educational efforts to reinforce the non-substitutability of PEDMARK.

Key Dates

Keywords

PEDMARK, sodium thiosulfate, FDA, ototoxicity, cisplatin, pediatric, healthcare providers, drug substitution, patient safety, pharmaceuticals